---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-003789"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2022-01-13T23:59:59+00:00"
generated_at: "2026-06-27T18:24:37.001373+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Journey Medical acquires VYNE's MST franchise for $20M upfront; credit facility expanded to $30M

## Summary
- Acquired AMZEEQ, ZILXI, FCD105, and MST platform for $20M upfront plus $5M at one year; contingent milestones up to $450M.
- Products generated ~$4M net sales in Q3 2021; portfolio now includes nine marketed dermatology products.
- Credit facility with East West Bank expanded to $30M: $10M revolver + $20M term loan to finance acquisition and working capital.
- Journey substituted as plaintiff in patent litigation against Padagis over Amzeeq; trial set for July 2023, stay until Dec 2023.

## SEC filing metadata
- accession: 0001104659-22-003789
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2022-01-13T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465922003789/0001104659-22-003789-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465922003789/tm222871d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-003789
- JSON: https://secwatch.observer/filing/0001104659-22-003789.json
- Plain text: https://secwatch.observer/filing/0001104659-22-003789.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.